Edesa Biotech Reports $1.7 Million Net Loss and Significant Cash Increase in Latest Filing

Edesa Biotech, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded a net loss of $1.7 million, or $0.25 per share, compared to a net loss of $1.7 million, or $0.52 per share, for the same period in 2024. For the nine months ended June 30, 2025, the net loss was $5.0 million, or $0.95 per share, down from a loss of $5.2 million, or $1.64 per share, in the prior year. Total operating expenses for the nine-month period decreased to $5.4 million from $6.0 million, primarily due to reduced research and development (R&D) costs.

The company’s cash and cash equivalents surged to $12.4 million as of June 30, 2025, up from $2.0 million at the end of the previous fiscal year. This increase was largely attributed to successful financing activities, including gross proceeds of approximately $15.0 million from the issuance of Series B-1 Preferred Shares and common shares in a private placement, as well as $1.5 million from the sale of Series A-1 Preferred Shares. Edesa's total assets rose to $14.8 million, compared to $3.8 million in the prior year, reflecting a substantial improvement in liquidity.

Strategically, Edesa Biotech has made notable advancements in its clinical pipeline, particularly with its drug candidates EB05 and EB06. The company is preparing for a Phase 2 clinical study of EB06, an anti-CXCL10 monoclonal antibody for treating vitiligo, and is involved in a U.S. government-funded clinical trial for EB05, which targets Acute Respiratory Distress Syndrome (ARDS). The company has also entered into a multi-year contribution agreement with the Canadian government, securing up to C$23 million in funding for its clinical studies.

Operationally, Edesa's R&D expenses for the nine months ended June 30, 2025, were $2.4 million, a decrease from $2.8 million in the previous year, primarily due to lower costs associated with EB05. The company’s total liabilities decreased to $0.7 million from $1.8 million, indicating improved financial health. Edesa's employee headcount remains stable, supporting its ongoing clinical and administrative functions.

Looking ahead, Edesa Biotech anticipates continued operating losses as it advances its product candidates and seeks regulatory approvals. The company plans to leverage its current cash reserves and financing activities to fund operations through fiscal 2026. However, management has indicated that additional funding will be necessary to support ongoing development and operational needs, emphasizing the importance of securing further financing through equity sales, grants, or strategic partnerships.